Glenn Heller

List of Publications by Year
in descending order

64 papers	5,622 citations
147801 31 h-index	155660 55 g-index
65 all docs	65 docs citations
65 times ranked	8776 citing authors

#	Article	IF	Citations
1	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , .	1.9	1
2	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	6.4	8
3	Concordance probability as a meaningful contrast across disparate survival times. Statistical Methods in Medical Research, 2021, 30, 816-825.	1.5	0
4	The added value of new covariates to the brier score in cox survival models. Lifetime Data Analysis, 2021, 27, 1-14.	0.9	4
5	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2209-2215.	7.0	65
6	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with *EGFR* Exon 20 Insertions. Clinical Cancer Research, 2021, 27, 2920-2927.	7.0	42
7	Pilot Study of Dacomitinib for Patients With Metastatic *EGFR*-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precision Oncology, 2021, 5, 695-700.	3.0	9
8	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology, 2021, 4, 543-552.	5.4	11
9	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 447-456.	1.9	3
10	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science, 2021, 34, 70-78.	0.4	3
11	Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis, 2020, 26, 856-871.	0.9	0
12	The Genomic Landscape of *SMARCA4* Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 2020, 26, 5701-5708.	7.0	133
13	CNS Metastases in Patients With MET Exon 14–Altered Lung Cancers and Outcomes With Crizotinib. JCO Precision Oncology, 2020, 4, 871-876.	3.0	14
14	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic *EGFR*-Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	7.1	96
15	Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. Nature Cancer, 2020, 1, 359-369.	13.2	25
16	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	3.0	93
17	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	7.1	839
18	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood, 2019, 134, 2361-2368.	1.4	190

#	Article	IF	Citations
19	Reply to C. Ren et al. Journal of Clinical Oncology, 2018, 36, 2354-2356.	1.6	0
20	Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1179.	7.1	190
21	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology, 2018, 36, 572-580.	1.6	187
22	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunology Research, 2018, 6, 900-909.	3.4	73
23	Inference for the difference in the area under the ROC curve derived from nested binary regression models. Biostatistics, 2017, 18, kxw045.	1.5	10
24	Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leukemia and Lymphoma, 2017, 58, 1859-1871.	1.3	54
25	Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European Urology, 2017, 71, 874-882.	1.9	150
26	Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research, 2017, 77, 5687-5698.	0.9	112
27	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical Cancer Research, 2017, 23, 1967-1973.	7.0	46
28	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology, 2017, 102, 164-172.	1.0	52
29	*KIR3DL1* Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. Journal of Clinical Oncology, 2016, 34, 2443-2451.	1.6	73
30	First-in-Human Imaging with [89]Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 2016, 57, 1858-1864.	5.0	116
31	Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1441.	7.1	535
32	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κBâ€"Controlled Oxidative Stress Responses. Cancer Research, 2016, 76, 377-389.	0.9	36
33	Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. Clinical Cancer Research, 2016, 22, 1341-1347.	7.0	5
34	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. Thyroid, 2016, 26, 219-226.	4.5	56
35	Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Analysis, 2016, 22, 263-279.	0.9	39
36	Everolimus combined with gefitinib in patients with metastatic castrationâ€"resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, 121, 3853-3861.	4.1	27

#	Article	IF	Citations
37	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1348-1355.	1.6	343
38	Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. European Urology, 2014, 65, 1191-1197.	1.9	66
39	A measure of explained risk in the proportional hazards model. Biostatistics, 2012, 13, 315-325.	1.5	51
40	Proportional hazards regression with interval censored data using an inverse probability weight. Lifetime Data Analysis, 2011, 17, 373-385.	0.9	23
41	A Novel Reduced Intensity Conditioning Can Induce a High Incidence of Sustained Donor Engraftment After Double Unit Cord Blood Transplantation (CBT) without Anti-Thymocyte Globulin. Blood, 2010, 116, 2351-2351.	1.4	0
42	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, The, 2009, 10, 233-239.	10.7	558
43	Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 2222-2222.	1.4	0
44	Human Langerhans-Type Dendritic Cells Break Tolerance against the Tumor Antigen, WT1, by a Largely IL-15-Dependent Mechanism.. Blood, 2008, 112, 1554-1554.	1.4	0
45	Improving the Decision to Pursue a Phase 3 Clinical Trial by Adjusting for Patient-Specific Factors in Evaluating Phase 2 Treatment Efficacy Data. Medical Decision Making, 2007, 27, 380-386.	2.4	5
46	Inference on the Limiting False Discovery Rate and the P-value Threshold Parameter Assuming Weak Dependence between Gene Expression Levels within Subject. Statistical Applications in Genetics and Molecular Biology, 2007, 6, Article14.	0.6	3
47	Smoothed Rank Regression With Censored Data. Journal of the American Statistical Association, 2007, 102, 552-559.	3.1	43
48	Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis. Statistics in Medicine, 2006, 25, 2543-2553.	1.6	2
49	Concordance probability and discriminatory power in proportional hazards regression. Biometrika, 2005, 92, 965-970.	2.4	539
50	Adoptive Transfer of In Vitro Generated T Cell Precursors Enhances Donor T Cell Reconstitution and Graft-Versus-Tumor Activity in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.. Blood, 2005, 106, 63-63.	1.4	1
51	Incorporating Follow-up Time in M-Estimation for Survival Data. Lifetime Data Analysis, 2004, 10, 51-64.	0.9	2
52	Picking the winners in a sea of plenty. Clinical Cancer Research, 2002, 8, 400-4.	7.0	14
53	An adjustment for a post-randomization variable in the comparison of two treatments for survival. Statistics in Medicine, 2001, 20, 3475-3485.	1.6	2
54	Neuroblastoma metastatic to the central nervous system. Cancer, 2001, 91, 1510-1519.	4.1	131

#	Article	IF	Citations
55	The Cox proportional hazards model with a partly linear relative risk function. , 2001, 7, 255-277.		13
56	Pairwise Rank-Based Likelihood for Estimation and Inference on the Mixture Proportion. Biometrics, 2001, 57, 813-817.	1.4	4
57	Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer, 2000, 89, 2122-2130.	4.1	18
58	Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8. , 1999, 82, 538-548.		12
59	T-Cellâ€"Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. Blood, 1998, 91, 1083-1090.	1.4	217
60	Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. , 1997, 29, 563-567.		7
61	The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer, 1996, 77, 791-798.	4.1	162
62	The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer, 1996, 77, 791-798.	4.1	7
63	The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer, 1994, 73, 109-117.	4.1	95
64	Primary peripheral nodal lymphoma in children. Cancer, 1993, 71, 3670-3679.	4.1	7